CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Sam Martin

Profile

Sam Martin

Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer), Celldex Therapeutics, Inc.

Leaving, effective March 31, 2027. First published here October 28, 2026; built from records as of October 28, 2026.

Sam Martin is leaving the chief financial officer seat at Celldex Therapeutics, Inc.: the company's filing of July 15, 2026 gives March 31, 2027 as the effective date.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Celldex Therapeutics, Inc. (CLDX)
In Vitro & In Vivo Diagnostic Substances
Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)Leaving, effective March 31, 20272

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. March 31, 2027takes effect

    Celldex Therapeutics, Inc. reported the departure of Sam Martin from the chief financial officer seat, effective March 31, 2027.

    On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.

    [2] Filing by Celldex Therapeutics, Inc., filed with the SEC on July 15, 2026. Read the filing. The record at CFO Tribune.

  2. February 25, 202610-K filed

    Sam Martin signed the annual report of Celldex Therapeutics, Inc. on Form 10-K as Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer), filed February 25, 2026.

    /s/ SAM MARTIN Senior Vice President, February 25, 2026 Sam Martin Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

    [1] Annual report on Form 10-K by Celldex Therapeutics, Inc., filed with the SEC on February 25, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, Celldex Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed February 25, 2026. sec.gov; record.
  2. Current report filed with the SEC, Celldex Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 15, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Sam Martin wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.